The Einstein Center for Epigenomics Signs Site License Agreement with CLC bio
News Mar 03, 2009
The Einstein Center for Epigenomics at the Albert Einstein College of Medicine in Bronx, New York, has entered into an agreement with CLC bio to put the company's full suite of bioinformatics tools into the hands of epigenomics researchers and other investigators at the College.
The suite includes CLC bio’s solutions for handling high-throughput sequencing data, CLC Genomics Workbench and CLC Genomics Server.
Dr. John Greally, director of the Einstein Center for Epigenomics, is enthusiastic about the multi-year partnership, noting, "CLC bio's tools are going to put sophisticated analytical ability into the hands of molecular biologists at Einstein, and will greatly enhance their ability to explore the massively-parallel sequencing data that we are generating. We see this as a way of lowering barriers for scientists who have not previously performed these high-throughput epigenomic assays, allowing them to explore their data and explore hypotheses."
CEO at CLC bio USA, Jan Lomholdt, comments, "We’re very happy to announce this site license agreement and look forward to working with and getting valuable feedback from world-renowned scientists at Einstein. This agreement is yet another stamp of approval by the scientific community in North America, where CLC bio is currently getting a strong foothold. We will be announcing more exciting agreements in the near future."
China is poised to introduce a new regulation on gene editing in humans. A draft of the country’s new civil code lists human genes and embryos in a section on personality rights to be protected. Experiments on genes in adults or embryos that endanger human health or violate ethical norms can accordingly be seen as a violation of a person’s fundamental rights.READ MORE